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Babesiosis was reported in a California resident who 
received a transfusion of blood products collected in the 
disease-endemic northeastern region of the United States. 
Babesiosis should be considered year-round in the diagno-
sis of febrile and afebrile patients with abnormal blood cell 
counts who have received blood products from disease-
endemic areas. 
B
abesiosis is an infection of red blood cells (RBCs) 
caused by various species of the protozoan genus 
Babesia. Most human infections reported in the United 
States are attributed to B. microti and occur most frequently 
in the Northeast and less commonly in the Midwest (1). 
Infrequently, babesiosis cases have been documented in 
California and Washington; however, these cases were 
caused by local Babesia-like isolates, including B. duncani 
and a B. divergens–like parasite (1–3). B. microti infection 
is often asymptomatic but can potentially be severe and 
even fatal, especially in the elderly, asplenics, and other 
immunosuppressed persons. Symptoms can be nonspeciﬁ  c, 
mimicking many systemic infectious diseases, and include 
fever, chills, myalgias, fatigue, and jaundice caused by 
hemolytic anemia (1).
Babesiosis is transmitted primarily through the bite of 
an infected tick, typically Ixodes spp., although occasion-
ally transmission occurs via transfusion of blood products 
collected from asymptomatic infected donors (1). More 
than 50 transfusion-related cases have been reported in the 
United States (4). This report describes a transfusion-ac-
quired case of babesiosis caused by B. microti in a resident 
of Los Angeles County, California. 
The Case
On February 12, 2007, a 58-year-old man with meta-
static esophageal cancer was admitted to an acute care fa-
cility for evaluation of hematemesis and normocytic ane-
mia. The initial examination showed he had hypotension 
without fever, joint swelling, headaches, or rash. Labora-
tory evaluation showed a hemoglobin concentration of 8.4 
mg/dL, a platelet count of 71,000/mm3, and a leukocyte 
count of 3.5 × 103/mm3 with 19% bands. Results of liver 
function tests showed mild elevations in levels of aspartate 
transaminase (202 mg/dL), alanine transaminase (33 mg/
dL), and total bilirubin (0.7 mg/dL). 
An abnormal blood cell count prompted a manual dif-
ferential count. Babesia spp. was identiﬁ  ed on a periph-
eral smear and subsequently conﬁ  rmed at the Los Angeles 
County Public Health Laboratory. The result of PCR anal-
ysis performed by a commercial laboratory was positive 
and highly speciﬁ  c for B. microti DNA, a result conﬁ  rmed 
by the Centers for Disease Control and Prevention (CDC) 
(Table). The commercial laboratory also performed indi-
rect ﬂ  uorescent antibody (IFA) testing for B. microti and 
found both acute and convalescent specimens to be nega-
tive. Conﬁ  rmatory testing at CDC corroborated the nega-
tive result for the acute specimen but showed the convales-
cent specimen, collected 8 days after onset, to be positive 
for B. microti, with a total antibody titer of 64. The patient 
was treated with azithromycin and atovaquone for 7 days, 
given 2 blood transfusions for anemia, and discharged in 
stable condition on February 16, 2007. 
Before admission, the patient had visited an oncology 
clinic numerous times for treatment related to his esopha-
geal cancer: radiation therapy in October 2006, 3 che-
motherapy courses from October 2006 through February 
2007, and blood transfusions in January 2007. The patient 
received 6 units of packed red blood cells (PRBCs) and 2 
units of fresh frozen plasma (FFP) over several clinic visits 
on January 1 and January 22–24, 2007. 
The patient was in Salt Lake City, Utah, from Janu-
ary 13 through January 20, 2007; however, because of poor 
health, he did not engage in any outdoor activities. At least 
a year before his admission in 2006, the patient visited an 
undeveloped property near Klamath Falls, Oregon, where 
he spent time outdoors. He could not recall ever incurring a 
tick bite, seeing ticks, or having any animal contact.
The Table summarizes the serologic and PCR results 
for specimens collected from the patient and 6 PRBC do-
nors. The PRBC units came from 2 blood banks: 1 in Maine 
(2 units) and 1 in California (4 units). A blood donor from 
Maine tested positive for B. microti by IFA, with a total 
antibody titer 256, but tested negative B. microti by PCR. 
Testing of specimens from remaining PRBC donors yield-
ed negative results. Specimens from FFP donors were not 
tested because of the low risk for Babesia spp. transmission 
associated with plasma products.
The implicated donor was a 49-year-old male resident 
of Maine, where babesiosis is less common than in other 
states in the northeast. For example, whereas Maine typi-
cally reports <12 cases annually, Rhode Island has reported 
up to 61 cases (5,6). However, the donor resided in the 
southern coastal region of the state, where Maine’s cases 
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is likely to have become infected in late August 2006, when 
he sought treatment for fever, chills, weight loss, and fa-
tigue and was tested for various infections, including Lyme 
disease and ehrlichiosis. At that time, he was not tested for 
babesiosis. His health improved without a speciﬁ  c diag-
nosis or treatment, and he remained asymptomatic, but he 
evidently was parasitemic when he donated blood on De-
cember 20, 2006. Blood products from this donation were 
included in the transfusion the patient received on January 
1, 2007. Between October 2005 and the blood donation on 
December 20, 2006, the donor made 3 donations.
All other recipients of blood products from this donor 
were residents of Maine. They were notiﬁ  ed of the need 
for serologic testing; none were reported to be infected (V. 
Rea, pers. comm.).
Conclusions
Babesiosis was documented in a man with metastatic 
cancer who resided in an area nonendemic for B. microti. 
On the basis of laboratory and epidemiologic informa-
tion, we concluded that the patient acquired the infection 
via transfusion of infected PRBCs donated in a disease-
endemic area thousands of miles away. The 12-day period 
from donation to transfusion was within the maximum 35 
days that B. microti has been known to remain viable in 
refrigerated blood (7). The period from time of transfusion 
exposure until positive smear was ≈6 weeks; incubation pe-
riods for transfusion-related cases have ranged from weeks 
to many months (B. Herwaldt, pers. comm.). We had ten-
tatively hypothesized that the patient might have acquired 
the infection in Oregon, where he spent substantial time 
outdoors, but remained asymptomatic until he became ill 
with cancer; however, we rejected this hypothesis because 
human cases of babesiosis have never been documented in 
Oregon (or in Utah where the man also visited) and because 
infections acquired in western states are more likely to be 
caused by local Babesia agents. 
This case demonstrates that, even among transfused 
patients who show atypical symptoms of babesiosis, the 
possibility of infection should be considered if they have 
received blood products from disease-endemic areas and 
display abnormal blood cell counts, such as low iron and 
low leukocyte counts. Generalized debilitation associated 
with cancer and chemotherapy may have masked Babesia-
related symptoms in this patient and undermined his im-
mune response. This case also underscores the widening 
seasonal and geographic boundaries of babesiosis. Tick-
borne babesiosis usually peaks from July through Sep-
tember (4), but because asymptomatic Babesia infection 
can persist for months to years, especially in untreated 
persons (7,8), transfusion-associated infection can occur 
throughout the year. Geographic limitations in babesiosis 
are virtually erased by the mobility of donors and blood 
products. The blood bank involved in this case has blood 
collection centers in California and Maine but provides 
blood products to hospitals throughout southern Califor-
nia and the East Coast. Medical evaluation for babesiosis 
in both febrile and afebrile transfusion patients should 
include a Giemsa-stained thin blood smear, an acute se-
rologic evaluation by IFA testing and a convalescent se-
rologic evaluation by IFA testing taken 4–6 weeks apart 
(9), and PCR evaluation of whole blood. 
The varied clinical spectrum of babesiosis makes its 
detection in blood donors challenging. This case exem-
pliﬁ  es the limitations in screening healthy asymptomatic 
donors for babesiosis. Available screening tests to detect 
Babesia spp. postdonation are not cost-effective and have 
inadequate sensitivity (7,10). Nucleic acid testing and in-
activation procedures may provide useful options for de-
tecting Babesia spp. in the future (7,11). Until effective 
screening procedures are available, however, diagnosis of 
babesiosis in blood donors will continue to be based pri-
marily on clinical observation. 
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Table. Results of serologic testing and PCR analyses of specimens collected from a California resident with babesiosis and donors of 
packed red blood cells, 2007*
B. microti test results
Specimen source  Residence Date of transfusion† Date of specimen collection PCR IFA
Patient California – Feb 12 Positive <8‡
Feb 20  – 64
Donor 1 Maine Jan 1  Feb 26 Negative 256
Donor 2 Maine Jan 1  Feb 26  – <8
Donor 3 California Jan 22  Feb 21  – <8
Donor 4 California Jan 23  Feb 22  – <8
Donor 5 California Jan 24  Feb 21  – <8
Donor 6 California Jan 24  Feb 21  – <8
*IFA, immunofluorescent antibody. 
†Involving blood products from specified donor. 
‡<8 is considered a negative titer for total B. microti antibody. IFA tests conducted at the Centers for Disease Control and Prevention Reference 
Diagnostic Laboratory. Babesiosis Acquired through Blood Transfusion
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etymologia etymologia
Babesia
[bə-be′ ze-ə]
A genus of protozoa of the order Piroplasmida, named for Victor Babès (1854–1926), a Romanian bacteriologist 
who discovered a parasitic sporozoon in ticks in 1885. The parasites occur within the erythrocytes of various 
vertebrates and cause babesiosis, a tick-borne infection of domestic animals and humans. 
Babès was also a coauthor of the ﬁ  rst text on bacteriology (Bacteria and Their Role in the Anatomy and 
Pathological Histology of Contagious Diseases, with French scientist A.V. Cornil); the ﬁ  rst to demonstrate 
the presence of tuberculous bacilli in the urine of infected patients; a founder of serum therapy; and the ﬁ  rst to 
introduce rabies vaccination to Romania.  
Sources:  Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: Saunders; 2007; www.whonamedit.com; www.ici.ro/
romania/en/stiinta/babes.html
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